logo

Publication in the scientific journal Biomedical Chromatography

Publication in the scientific journal Biomedical Chromatography

Leave a Comment / Uncategorized / By
We are pleased to share that a study developed by Moehs’ Research and Development team has been published in the scientific journal Biomedical Chromatography. This research focuses on nitroso-duloxetine impurity, a compound classified as a potentially genotoxic impurity, reinforcing our commitment to pharmaceutical safety and innovation.
 

Given the stringent requirements for controlling nitrosamines at parts-per-billion (ppb) levels, developing precise and reliable analytical methods is essential. At Moehs, we have successfully designed and validated a simple yet highly sensitive UHPLC-MS/MS method for the determination of nitroso-duloxetine in Duloxetine HCl drug substance.

This milestone underscores our dedication to advancing pharmaceutical analysis and ensuring the highest quality standards in API manufacturing.

Read here the full study.

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.